Date: 2013-07-08
Type of information: Grant
Company: Sensorion (France) Griffin Discoveries (the Netherlands)
Investors:
Amount: € 1.1 million
Funding type: grant
Planned used: The grant will be used to map the function of histamine receptors in the inner ear and develop a new histamine H4 receptor antagonist for the treatment of vestibular disorders.
Others: * On July 8, 2013, Sensorion and Griffin Discoveries have been awarded a grant through the 1.1 M€ Eureka Eurostars program for the joint development of new therapies for vestibular disorders. Griffin Discoveries and Sensorion team up to bring an innovative solution for the treatment of vestibular disorders which are characterized by debilitating symptoms including dizziness, visual disturbances and balance impairment. This family of disorders that include, Meniere’s disease and vertigo crisis currently represent an area of truly unmet medical need.
In the Eurostars program H4 INVEST, both SMEs will jointly map the function of histamine receptors in the inner ear and develop a new histamine H4 receptor antagonist for the treatment of vestibular disorders. The histamine H4 receptor is the most recently added member of the histamine receptor family that holds great promise for the treatment of a variety of diseases including allergic asthma and atopic dermatitis. More recently Sensorion scientists have described the role of the H4R in vestibular dysfunction and identified this G protein-coupled receptor as a novel therapeutic target.
Therapeutic area: Otorhinolaryngology
